A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents (MATCH-R)

Gustave Roussy

Status

Completed

Conditions

Metastatic Oncogen-driven Cancer

Treatments

Procedure: Biopsy

Study type

Interventional

Funder types

Other

Identifiers

NCT02517892

2014-A01147-40

2014/2144 (Other Identifier)

Details and patient eligibility

About

This is a prospective study to identify molecular mechanisms of acquired resistance to targeted therapies in patients with unresectable or metastatic cancer.

This is a protocol to study clinical characteristics and biopsy tissue of patients with oncogene-driven cancer who have had previous clinical response to targeted therapy and subsequently experience progression of disease. The tissues and other specimens will be used to carry out laboratory studies to explore the molecular basis of acquired resistance to targeted therapies.

Enrollment

1,500 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients diagnosed with confirmed cancer and who fulfill the following eligibility criteria will be considered eligible for this study:

Patient affiliated to a social security regimen
Patients scheduled to receive anticancer agents or currently receiving anticancer agents
Tumor lesion accessible to core biopsies (malignant effusions can represent an alternative)
Patient who is fully informed, able to comply with the protocol and who signed the informed consent.
Availability of initial tumor material (ideally frozen, or non-Bouin fixed paraffin embedded material) acquired before exposure to the targeted therapy Note: Patients may have received other treatments since treatment with targeted therapies including radiation or chemotherapy, before undergoing the study biopsy.

Exclusion criteria